A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 1441
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : SGLT2
Long Form : sodium-glucose cotransporter 2
No. Year Title Co-occurring Abbreviation
2020 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). ADA, CKD, CVD, EASD, GLP-1, hHF, MACE
2020 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). ADA, CKD, CVD, EASD, GLP-1, HHF, MACE
2020 A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus. ED, FG
2020 A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet. euDKA
2020 A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. SIAD
2020 A Review of the Renoprotective Effects of Novel Antidiabetic Agents. DPP-4, GLP-1
2020 Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. DPP4, GLP-1
2020 Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme. BMI
2020 An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option. T1D, T2D
10  2020 An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions. AUC, tmax
11  2020 Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence. ECs, HG, NO
12  2020 Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model. OCT, TNF
13  2020 Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. GLP-1, HCC, NAFLD, NASH, T2D
14  2020 Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. ---
15  2020 Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. GLP-1, HRs
16  2020 Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors. ---
17  2020 Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update. ---
18  2020 Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult. ---
19  2020 Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells. AGT, CANA, HG, PTCs
20  2020 CaMKII and GLUT1 in heart failure and the role of gliflozins. ---
21  2020 Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARalpha in vivo and in vitro. HFD, WAT
22  2020 Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study. ---
23  2020 Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1. HO-1, Nrf2, ROS, SMCs
24  2020 Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity. ---
25  2020 Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. HF, T2D
26  2020 Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials. ---
27  2020 Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes. ---
28  2020 Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials. CKD, DM
29  2020 Cardiovascular protection with SGLT2 inhibitors in type 2 diabetes mellitus: does it apply to all patients? CVD, T2D
30  2020 Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication. ATC, DPP-4, GLP-1, OR
31  2020 Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. BMI, CI, HRs
32  2020 Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care. BMI, BP, CI, DPP-4, eGFR, SUs
33  2020 Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin. AUC
34  2020 Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes. EPO, HIF, RAS, REPs
35  2020 Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. ICERs, QALYs, T1DM
36  2020 Cost-effectiveness of diabetes treatment sequences to inform step therapy policies. DPP-4, GLP-1RA, ICER
37  2020 Critical Examination of Mechanisms Underlying the Reduction in Heart Failure Events With SGLT2 Inhibitors: Identification of a Molecular Link Between Their Actions to Stimulate Erythrocytosis and to Alleviate Cellular Stress. SIRT1
38  2020 DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. CV, EF, HF
39  2020 Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. ---
40  2020 Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature. T2DM
41  2020 Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. CVOT, RCT, T2DM
42  2020 Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice. HFD, NAFLD
43  2020 Diabetes mellitus impairs circulating proangiogenic granulocytes. PAGs
44  2020 Doxazosin down-regulates sodium-glucose cotransporter-2 and exerts a renoprotective effect in rat models of acute renal injury. ARI, ERK, HIF-1alpha, iNOS, IR, MDA, NO, PGE2, SBP
45  2020 Drug Therapy in Obesity: A Review of Current and Emerging Treatments. GIP, GLP-1, MC4R, NPY
46  2020 Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. G6Pase, PEPCK, T2D
47  2020 Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study. DPP-4, T2DM
48  2020 Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes. STZ
49  2020 Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. AF, AFL, HF, HR
50  2020 Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. HFrEF
51  2020 Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules. CREB, FOXO1, G6Pase, PEPCK, PGC-1alpha
52  2020 Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. GLP-1, NAFLD
53  2020 Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease. CI, HR
54  2020 Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor. AST, DPP-4, gamma-GTP, HbA1c
55  2020 Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease. BP, CKD, LF, MAP, SAP, SNA
56  2020 Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis. CVD, DPP-4, GLP-1, LV, LVEDD, LVEDV, LVEF, LVESV, MET, SU, TZDs
57  2020 Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). CANDLE, CHF, CI, LVEF, NT-proBNP, T2D
58  2020 Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). CANA, CON, HCC
59  2020 Effects of ertugliflozin on renal function over 104weeks of treatment: a post hoc analysis of two randomised controlled trials. UACR
60  2020 Effects of sodium glucose co-transporter 2 inhibitors on genital infections in female patients with type 2 diabetes mellitus- Real world data analysis. HMO, HR, T2DM
61  2020 Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. CENTRAL, CIs, RCTs, RR
62  2020 Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. ---
63  2020 Effects of sodium-glucose co-transporter-2 inhibitors on serum alanine aminotransferase levels in people with type 2 diabetes: A multi-institutional cohort study. CI, T2D, ULN
64  2020 Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis. DVT, PE, RR, VTE
65  2020 Effects of sodium-glucose cotransporter2 inhibitors on non-alcoholic fatty liver disease in patients with type2 diabetes: A meta-analysis of randomized controlled trials. CI, NAFLD, WMD
66  2020 Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus. CVD, E/A, EF, LAD, T2DM
67  2020 Efficacy and safety of metformin and sodium-glucose co-transporter-2 inhibitors in adults with type1 diabetes: A systematic review and network meta-analysis. CI, DKA, T1DM, WMD
68  2020 Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). DPP-4
69  2020 Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report. DM, GLP-1, PWS
70  2020 Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. MGO, PVAT, STZ
71  2020 Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats. AKI, DM, MI
72  2020 Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. I/R
73  2020 Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. NASH, T2DM
74  2020 Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure. HF, MI
75  2020 European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. DPP-4, GLP-1RA, HF, T2DM
76  2020 Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors. ---
77  2020 Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. DPP4, eGFR, HbA1c, SBP
78  2020 Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). DPP-4, MAGE, MTTs
79  2020 GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice. GLP-1RA
80  2020 Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. CV, NAFLD, UGE
81  2020 How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. GLP-1, GLP-1RA
82  2020 Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial. AMI
83  2020 Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. CKD, eGFR, UACR, UPCR
84  2020 Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. DAPA, EGP, FPG, T2D, UGE
85  2020 Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance. Adipo-IR, ANCOVA, CI
86  2020 Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization. beta-OHB, SCOT
87  2020 Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets. ---
88  2020 Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework. AMPK, SIRT1
89  2020 Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. eGFR
90  2020 Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. ESPVR, FS, LAD, LV, LVEDP, MI, P-V, PRSW, SBP
91  2020 Long-term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. CI
92  2020 Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. CENP-A, FOXM1, Plk1
93  2020 Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes. eGFR
94  2020 Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. HF, T2DM
95  2020 Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce CardiovascularRisk in Adults With Type 2 Diabetes Mellitus. CV, GLP-1
96  2020 Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans. ---
97  2020 Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors. AMPK, SIRT1
98  2020 Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus. Emax, FPG, HbA1c, T2DM, UGE
99  2020 No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro. PTCs
100  2020 Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. ACE, ARBs, DKD, MRAs